Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Patient's organoids predict response to chemotherapy

The organoid-based test, developed by the group of Emile Voest at Netherland’s Cancer Institute in Amsterdam, in a prospective clinical trial...

Researchers identify CTLA-4 response marker

The research team headed by Simon Heideger and Hendrick Poeck from Technical University of Munich together with colleagues from Memorial Sloan...

Research team improves safety of LGMD2A gene therapy

Limb-girdle muscular dystrophy type 2A (LGMD2A or LGMDR1) is a neuromuscular disorder hat causes progressive muscle weakness and has no cure. The...

2nd ECP Summer Summit at Henkel HQ, Düsseldorf

On September 26, international representatives from startups, SMEs, large companies. clusters, industry parks and further services providers came...

Researchers unravel how ADEP antibiotics work

Fighting antimicrobial resistance has been named one of the prioritary goals by the World Health Organization (WHO). However, as the number of...

UniQure looking to raise US$200m

The Amsterdam-based company announced that it had commenced an underwritten public offering of US$200m of its ordinary shares. uniQure also intends...

Novo secures Dicerna’s RNAi liver assets

Under the deal, which includes potential treatments for NASH, orphan liver diseases, obesity and diabetes, Dicerna could theoretically earn...